| scholarly article | Q13442814 |
| P50 | author | Bashar Ibrahim | Q37837830 |
| P2093 | author name string | Kaivan Khavandi | |
| Halima Amer | |||
| Jack Brownrigg | |||
| P2860 | cites work | Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals | Q21245270 |
| Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association | Q22241916 | ||
| Long term pharmacotherapy for obesity and overweight: updated meta-analysis. | Q22242086 | ||
| Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects | Q22250885 | ||
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult-Onset Diabetes Mellitus | Q24535547 | ||
| Are statins diabetogenic? | Q24630205 | ||
| 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study | Q24633604 | ||
| Treating prediabetes with metformin: systematic review and meta-analysis | Q24642274 | ||
| Borderline Diabetics and Their Response to Tolbutamide | Q54563818 | ||
| Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | Q57245141 | ||
| Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial | Q57274347 | ||
| Progression to Type 2 Diabetes Characterized by Moderate Then Rapid Glucose Increases | Q59150492 | ||
| Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study | Q60209721 | ||
| Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group | Q73733743 | ||
| Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial | Q77745899 | ||
| Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats | Q81321954 | ||
| Voglibose for prevention of type 2 diabetes mellitus | Q83733397 | ||
| A renaissance for cardio-metabolic surgery: better outcomes and lower costs? | Q84369744 | ||
| CAPPP trial. Captopril Prevention Project | Q95301625 | ||
| International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes | Q24642456 | ||
| Activation of the peripheral endocannabinoid system in human obesity | Q24655297 | ||
| Prevalence, predisposition and prevention of type II diabetes | Q24815863 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo | Q27999767 | ||
| Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
| Homo obesus: a metabotrophin-deficient species. Pharmacology and nutrition insight | Q28236345 | ||
| Long-term mortality after gastric bypass surgery | Q28241874 | ||
| NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel | Q28248503 | ||
| Impaired fasting glucose and impaired glucose tolerance: implications for care | Q28290479 | ||
| Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration | Q28378259 | ||
| A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents | Q28578730 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery | Q29614192 | ||
| Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study | Q29615122 | ||
| Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus | Q29616284 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials | Q29622947 | ||
| Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. | Q30350045 | ||
| Bariatric surgery: a systematic review and meta-analysis | Q30769299 | ||
| Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study | Q31829404 | ||
| Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose | Q31979462 | ||
| Effect of sibutramine on weight maintenance after weight loss: a randomised trial | Q33128832 | ||
| Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. | Q33213285 | ||
| Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial | Q33425402 | ||
| Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study--secondary analysis of the randomized trial | Q33455816 | ||
| Standards of medical care in diabetes--2010. | Q33554238 | ||
| The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study | Q33579765 | ||
| Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial | Q33658002 | ||
| Diabetes mellitus, fasting glucose, and risk of cause-specific death | Q33945937 | ||
| Effect of ramipril on the incidence of diabetes | Q33999592 | ||
| Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. | Q37022811 | ||
| Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat | Q37035477 | ||
| Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions | Q37061253 | ||
| Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006 | Q37067113 | ||
| Meta-analysis: metformin treatment in persons at risk for diabetes mellitus | Q37080248 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| A critical review of the cannabinoid receptor as a drug target for obesity management | Q37249756 | ||
| Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. | Q37304741 | ||
| Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. | Q37317415 | ||
| Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis | Q37409707 | ||
| Prediabetes: a high-risk state for diabetes development. | Q37476370 | ||
| From endocannabinoid profiling to 'endocannabinoid therapeutics'. | Q37508459 | ||
| Role of renin-angiotensin system blockade in patients with diabetes mellitus | Q37592697 | ||
| The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus | Q37637857 | ||
| Pathophysiology of prediabetes | Q37833737 | ||
| Preservation of β-cell function: the key to diabetes prevention | Q37893344 | ||
| Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care | Q37894484 | ||
| Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials | Q37924039 | ||
| Assessing corneal nerve structure and function in diabetic neuropathy | Q38010758 | ||
| Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets | Q38027826 | ||
| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 | ||
| Effects of intensive blood-pressure control in type 2 diabetes mellitus | Q34008161 | ||
| Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity | Q34028741 | ||
| Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota | Q34057383 | ||
| Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials | Q34083400 | ||
| Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects | Q34136304 | ||
| Gut hormone PYY(3-36) physiologically inhibits food intake | Q34143493 | ||
| Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments | Q34153575 | ||
| The prevalence of and factors associated with diabetic retinopathy in the Australian population | Q34199750 | ||
| Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program | Q34312885 | ||
| Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease | Q34432935 | ||
| Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial | Q34494637 | ||
| Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. | Q34541234 | ||
| Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study | Q34556870 | ||
| The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes | Q34576196 | ||
| Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis | Q34604680 | ||
| Multicenter, placebo-controlled trial of lorcaserin for weight management | Q34660152 | ||
| Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention | Q34808433 | ||
| Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q34862358 | ||
| Risk assessment tools for identifying individuals at risk of developing type 2 diabetes | Q35095114 | ||
| Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program | Q35568881 | ||
| Prevention or delay of type 2 diabetes | Q35615529 | ||
| JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice | Q35808362 | ||
| Five stages of evolving beta-cell dysfunction during progression to diabetes | Q35961960 | ||
| Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms | Q36020654 | ||
| Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition | Q36030068 | ||
| Endocannabinoid control of food intake and energy balance | Q36108722 | ||
| Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose | Q36462545 | ||
| Diabetic cardiovascular autonomic neuropathy | Q36715017 | ||
| Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies | Q36865276 | ||
| Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review | Q36883792 | ||
| European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep | Q36921892 | ||
| SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete | Q36945310 | ||
| Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant | Q36954706 | ||
| Statins are diabetogenic--myth or reality? | Q38028072 | ||
| Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial | Q38392749 | ||
| Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial | Q38486659 | ||
| Predictive value of HbA1c for incident diabetes among subjects with impaired glucose tolerance--analysis of the Indian Diabetes Prevention Programmes | Q39724630 | ||
| Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. | Q40248226 | ||
| The clinical implications of impaired glucose tolerance | Q41246275 | ||
| Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card | Q41824843 | ||
| Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q42950914 | ||
| Effect of nateglinide on the incidence of diabetes and cardiovascular events | Q43130181 | ||
| Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study | Q43255700 | ||
| Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy | Q43687920 | ||
| United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. | Q43810405 | ||
| Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study | Q44113847 | ||
| Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women | Q44114894 | ||
| Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention | Q44333422 | ||
| The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. | Q44333525 | ||
| The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial | Q44417511 | ||
| Mode of onset of type 2 diabetes from normal or impaired glucose tolerance | Q44704987 | ||
| Nephropathy in diabetes | Q44705106 | ||
| Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes | Q44705123 | ||
| Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients | Q44865611 | ||
| The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism | Q44992657 | ||
| Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). | Q45113788 | ||
| Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats | Q45147944 | ||
| Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). | Q45208371 | ||
| Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. | Q45271809 | ||
| Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. | Q46036413 | ||
| The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI <35 kg/m2. | Q46077828 | ||
| Withdrawal of Rimonabant--walking the tightrope of 21st century pharmaceutical regulation? | Q46102559 | ||
| Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial | Q46300946 | ||
| Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality | Q46366811 | ||
| Secular trends in cardiovascular disease risk factors according to body mass index in US adults | Q46446083 | ||
| The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study | Q46576373 | ||
| Normal fasting plasma glucose levels and type 2 diabetes in young men. | Q46738240 | ||
| X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. | Q46747380 | ||
| Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia | Q46807918 | ||
| Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study | Q46815611 | ||
| The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). | Q46878587 | ||
| Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus? | Q47240927 | ||
| Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters | Q47356520 | ||
| Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial | Q47381748 | ||
| Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. | Q50592928 | ||
| Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
| Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. | Q51371647 | ||
| Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. | Q51466685 | ||
| Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. | Q51470643 | ||
| Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. | Q51474202 | ||
| Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. | Q51496559 | ||
| Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. | Q51562831 | ||
| Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. | Q52871759 | ||
| P433 | issue | 5 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 242-261 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Therapeutic advances in chronic disease | Q26842871 |
| P1476 | title | Strategies for preventing type 2 diabetes: an update for clinicians | |
| P478 | volume | 4 |
| Q35025285 | A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy |
| Q38204472 | Antidiabetic plants improving insulin sensitivity |
| Q64908000 | Body Weight Considerations in the Management of Type 2 Diabetes. |
| Q37368103 | Body mass index: a risk factor for retinopathy in type 2 diabetic patients |
| Q41363134 | Chemical and Biological Aspects of Extracts from Medicinal Plants with Antidiabetic Effects |
| Q26751351 | Conceptualizing type 2 diabetes and its management |
| Q46626562 | Determining the optimal screening interval for type 2 diabetes mellitus using a risk prediction model. |
| Q92783543 | Effect of Steviol Glycosides on Human Health with Emphasis on Type 2 Diabetic Biomarkers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q51269837 | Effects of Obex in Overweight and Obese Subjects With or Without Impaired Fasting Glucose: A Pilot Study. |
| Q38393219 | Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia |
| Q34023579 | Novel treatment approaches in hypertensive type 2 diabetic patients |
| Q40021903 | Older Age, Higher Body Mass Index and Inflammation Increase the Risk for New-Onset Diabetes and Impaired Glucose Tolerance in Patients on Peritoneal Dialysis |
| Q91455159 | Patterns of changes in overtime working hours over 3 years and the risk for progression to type 2 diabetes in adults with pre-diabetes |
| Q64265346 | Potential antidiabetic effect of ethanolic and aqueous-ethanolic extracts of leaves on streptozotocin-induced diabetes in rats |
| Q36273209 | Prevention of type 2 diabetes through lifestyle modification: is there a role for higher-protein diets? |
| Q37636031 | Sulforaphane attenuation of type 2 diabetes-induced aortic damage was associated with the upregulation of Nrf2 expression and function |
| Q34096962 | Sweet taste sensitivity in pre-diabetics, diabetics and normoglycemic controls: a comparative cross sectional study |
| Q92533844 | The Association Between Prediabetes and Dyslipidemia Among Attendants of Primary Care Health Centers in Jeddah, Saudi Arabia |
| Q33883452 | The prevalence of impaired fasting glucose and undiagnosed diabetes mellitus and associated risk factors among adults living in a rural Koladiba town, northwest Ethiopia |
| Q35822736 | Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow |
Search more.